Opening: Real Consultation Scenario
Consultation Scenario — A 39-year-old woman with an AMH of 1.3 and a history of a terminated pregnancy due to trisomy 13, sitting in a reproductive center clinic in Bishkek, holding her previous chromosome report, asks: “In my case, can third-generation IVF screen out embryos with chromosomal abnormalities? What is the specific process?” This is a typical consultation in the daily outpatient clinic of a Bishkek third-generation IVF hospital.
What Problem Does Third-Generation IVF (PGT) Solve?
Preimplantation Genetic Testing (PGT, the third-generation IVF technology) primarily screens embryos for chromosomal number abnormalities, structural abnormalities, or monogenic diseases before transfer. For individuals with the following conditions, PGT can significantly improve transfer efficiency, reduce miscarriage rates, and lower the risk of birth defects:
- Chromosomal structural abnormalities (e.g., balanced translocation, Robertsonian translocation) carriers;
- Recurrent miscarriage (caused by embryonic chromosomal abnormalities);
- Advanced maternal age (female age ≥38, with a significantly increased rate of embryonic aneuploidy);
- Monogenic diseases (e.g., thalassemia, spinal muscular atrophy);
- Repeated implantation failure (considering embryonic factors after excluding uterine factors).
It is important to clarify: PGT cannot improve egg quality or enhance endometrial receptivity; it only addresses the screening of genetic aspects of the embryo.
Key Indicator Interpretation: Which Tests Determine Eligibility for a PGT Cycle?
Reproductive centers in Bishkek typically require patients to complete a comprehensive fertility assessment before starting a cycle. The following indicators directly influence protocol selection and success rate expectations:
| Indicator | Reference Range / Significance | Impact on PGT Cycle |
|---|---|---|
| AMH | ≥1.0 ng/mL indicates adequate ovarian reserve; 0.5–0.9 ng/mL indicates low reserve; <0.5 ng/mL indicates severely diminished reserve |
Very low AMH may lead to insufficient oocyte yield, affecting the number of embryos available for screening, thereby reducing the benefit of PGT. |
| FSH | Basal FSH (day 2-3 of menstruation) <10 IU/L is normal; 10–15 IU/L indicates diminished ovarian reserve |
Elevated FSH often accompanies poor ovarian response, requiring adjustment of stimulation medication dosage. |
| LH | Basal LH 2–8 IU/L; LH/FSH ratio >2 requires investigation for PCOS |
Abnormal LH levels may affect the synchrony of follicular development, thereby impacting oocyte quality. |
| Antral Follicle Count (AFC) | Bilateral follicle count ≥8 is normal; 5–7 is reduced; <5 is severely reduced |
AFC is one of the most direct predictors of oocyte yield, directly influencing the size of the embryo pool available for PGT screening. |
| Semen Analysis | Concentration ≥15×10⁶/mL; Progressive motility ≥32%; Normal morphology ≥4% |
When sperm DNA fragmentation index (DFI) >30%, it may affect embryo developmental potential; male factor issues should be addressed first. |
| Chromosome Karyotype | 46,XX or 46,XY; Abnormal karyotype requires genetic counseling |
Structural abnormalities like balanced translocation or Robertsonian translocation are clear indications for PGT-SR. |
Bishkek Third-Generation IVF Medical Procedure and Timeline
A complete PGT cycle, from pre-cycle preparation to the end of transfer, typically takes 3–4 months, with the stay in Bishkek lasting approximately 25–30 days. The standardized process is as follows:
Phase 1: Remote Preparation (Recommended 2–3 months in advance)
- Document Preparation: Passport (validity must cover the entire cycle, recommended remaining validity >6 months), visa (Bishkek offers e-visa or visa-on-arrival for some nationalities, but advance confirmation is recommended), notarized marriage certificate (required by some centers).
- Examination and Record Establishment: Complete female AMH, hormone panel (FSH, LH, E2, etc.), thyroid function, infectious disease screening, chromosome karyotype; male semen analysis, sperm DFI, infectious disease screening, chromosome karyotype. Some tests (e.g., chromosome karyotype) take 10–15 days for results and should be prioritized.
- Genetic Counseling: If there is a family history of genetic disease or a history of adverse pregnancy outcomes, provide the proband's diagnostic report for the reproductive geneticist to assess the feasibility of PGT-M/PGT-SR.
Phase 2: Ovarian Stimulation and Egg Retrieval in Bishkek (Approximately 12–14 days)
- Menstrual Cycle Day 2–3: Visit the clinic for ultrasound + hormone tests to confirm readiness for initiation. A stimulation protocol (commonly antagonist or PPOS protocol) is chosen based on AMH and AFC.
- Stimulation Medication: Daily injections of gonadotropins (FSH/LH preparations), average duration 10–12 days. Monitoring of hormones and follicle development occurs 3–5 times during this period.
- Trigger (Trigger Shot): When follicles reach 18–20mm, hCG or a GnRH agonist is administered. Egg retrieval takes place 36 hours later.
- Egg Retrieval Procedure: Performed under intravenous sedation via transvaginal ultrasound guidance, lasting 15–25 minutes. Patients can leave after a 2-hour observation period. The male partner provides a semen sample on the same day.
Phase 3: Embryo Culture and PGT Testing (Approximately 5–7 days lab work + 10–14 days waiting for results)
- Fertilization and Culture: ICSI is used for fertilization. Embryos are cultured to the blastocyst stage on day 5–6. A biopsy of 5–10 trophectoderm cells is taken for genetic testing.
- PGT Testing: NGS (Next-Generation Sequencing) or aCGH technology is used to detect chromosomal copy number variations. PGT-M requires additional design of probes for monogenic diseases, which takes longer (approximately 4–6 weeks).
- Embryo Cryopreservation: Biopsied blastocysts are vitrified and stored while awaiting test results.
| Phase | Estimated Time | Key Points |
|---|---|---|
| Remote Preparation (Tests + Visa) | 8–12 weeks | Prioritize chromosome karyotype, AMH, sperm DFI |
| Stimulation + Egg Retrieval (in Bishkek) | 12–14 days | Start on menstrual cycle day 2–3 |
| Embryo Culture + PGT Testing | 14–21 days | Can return home to wait for results or stay locally |
| Frozen Embryo Transfer (Return to Bishkek) | 10–14 days | Endometrial preparation needed in natural or artificial cycle |
Cost Breakdown and Influencing Factors
The cost of third-generation IVF in Bishkek is generally lower than in Europe, the United States, and some East Asian countries, but the exact amount varies significantly depending on the individual's protocol. The main cost components include:
- Pre-cycle Examination Fees: Fertility assessment for both partners + genetic screening, accounting for approximately 10%–15% of the total cost.
- Stimulation Medication Fees: Depending on AMH levels and ovarian response, medication dosage can vary by 2–3 times. Low AMH requires higher doses, increasing medication costs.
- Egg Retrieval + ICSI + Embryo Culture Fees: Includes laboratory procedures, forming the core of the cost.
- PGT Testing Fees: Charged per embryo. Testing 3–5 embryos usually falls in the mid-range; if fewer embryos are available for testing, the cost per embryo is higher.
- Freezing + Transfer Fees: Includes embryo cryopreservation, endometrial preparation, and transfer procedure.
It is important to note: If PGT-M (monogenic disease testing) is required, an additional fee for probe design is necessary, and the design process takes about 4–6 weeks. Confirm with the reproductive center in advance whether this fee is included in the total quote.
Suitable Candidates and Unsuitable Candidates
Suitable Candidates for a Bishkek PGT Cycle
- Women aged 38–43, with AMH ≥0.8, and a history of miscarriage due to embryonic chromosomal abnormalities;
- Couples where one partner is a carrier of a balanced translocation or Robertsonian translocation;
- Individuals with a clear risk of a monogenic disease, with the pathogenic gene already identified;
- Those with repeated implantation failure (≥2 attempts), after excluding uterine factors such as intrauterine adhesions, thin endometrium, or chronic endometritis;
- Individuals with reasonable confidence in egg or sperm quality, having previously formed at least 2–3 blastocysts.
Unsuitable Candidates or Those Requiring Cautious Evaluation
- AMH <0.5 and AFC <4: Expected oocyte yield is usually ≤3, and after blastocyst formation and testing, there may be no embryos available for transfer. Evaluating donor egg options is recommended first.
- Age ≥45: Even if embryos are obtained, the rate of chromosomal normality is extremely low (<5%), making the clinical value of PGT limited.
- Uncontrolled endometrial pathology: Conditions like intrauterine adhesions, endometrial polyps, or chronic endometritis should be treated before considering transfer.
- Both partners have not completed genetic counseling: If unknown pathogenic genes are carried, PGT cannot perform targeted testing, potentially leading to false-negative results.
Clinician Observation: Common Issues in Bishkek Clinical Practice
1. The “Threshold” of AMH
Many consultants believe that an AMH below 1.0 means they “cannot do IVF.” In reality, for patients with AMH 0.6–0.9, Bishkek reproductive centers use mild stimulation or PPOS protocols, and about 40%–50% still manage to obtain at least one blastocyst for PGT. The key lies in predicting ovarian response and adjusting medication accordingly.
2. Male Factor is Often Underestimated
In cases of repeated implantation failure, about 25%–30% are related to high sperm DNA fragmentation. Even if routine semen parameters are normal, a DFI test is recommended. When DFI >30%, it is advisable to first try antioxidant therapy or testicular sperm extraction before starting the cycle.
3. The Risk of “No Embryo Available for Transfer” After Biopsy
This is the greatest uncertainty in a PGT cycle. For example, in a 39-year-old woman, retrieving 8–10 eggs may yield 3–4 blastocysts. After PGT, the rate of chromosomal normality is about 25%–35%, potentially resulting in 0–1 embryo available for transfer. Patients must fully understand this risk before starting the cycle.
Frequently Asked Questions
Q: When should overseas IVF tests be done? How far in advance?
It is recommended to complete all tests 2–3 months in advance. Chromosome karyotype results take 10–15 days; AMH, hormone panel, and infectious disease screening take about 3–7 days. Passport validity should ideally have more than 6 months remaining. Visa processing time varies by country, usually allowing 3–4 weeks.
Q: Can I still do overseas third-generation IVF with low AMH?
AMH 0.5–0.9 still offers a chance. Protocols in Bishkek tend to use PPOS or mild stimulation. Although the oocyte yield is low (usually 2–5), if 1–2 blastocysts are formed and pass PGT, there is still a transfer opportunity. When AMH <0.5, a comprehensive assessment combining AFC and age is necessary. Some may try 1–2 cycles; if the oocyte yield is consistently ≤2, donor eggs should be considered.
Q: What preparations are needed for advanced maternal age overseas IVF?
Key tests for the woman: AMH, FSH, AFC, chromosome karyotype, hysteroscopy (to rule out endometrial pathology). Key tests for the man: Semen analysis + DFI. Additionally, the risk of miscarriage is higher in advanced maternal age. PGT can reduce but cannot completely eliminate the risk of embryonic abnormalities. It is advisable to consult a geneticist to understand the residual risk.
Q: Is pre-IVF optimization necessary before overseas treatment?
If thyroid dysfunction (TSH >2.5 mIU/L), vitamin D deficiency, insulin resistance, or obesity (BMI >28) are found, it is recommended to optimize for 2–3 months first. These factors affect egg quality and endometrial receptivity but are not directly related to PGT screening efficiency. Optimization cannot replace PGT but can improve overall cycle outcomes.